Higher rates of mortality seen among patients with systemic lupus erythematosus, with disparities by sex, race and ethnicity, and region.

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva has the potential to ...

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

About Gazyva/Gazyvaro Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 ...

A new study examined whether urinary biomarkers could predict future kidney complications in individuals with lupus nephritis ...

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the ...

The MAJESTY global phase 3 study evaluating obinutuzumab (Gazyva) in primary membranous nephropathy (PMN) demonstrated ...

Whether you’re been experiencing a dull ache, chronic dryness or eye pain that just won’t go away with standard ...

Kidney disease rarely announces itself loudly. It builds slowly, often without pain, and reduces kidney function over years. Chronic Kidney Disease (C.

Chronic fatigue or joint pain? It could be autoimmune. Learn how to get tested and what new biologic drugs could mean for treatment.

XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) ...

Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided ...